Moderna, Inc. / Lonza Group AG

COVID-19 vaccine manufacturing (mRNA-1273 / Spikevax — strategic supply agreement, not a therapeutic indication)

260M US cases/yr · $18.5B Moderna 2021 net product sales (USD MM, predominantly Spikevax) · 1100000 Cumulative US COVID-19 deaths through May 2023

Disease Overview

COVID-19, caused by SARS-CoV-2, was declared a global pandemic by the WHO on 11 March 2020. By the time Moderna and Lonza inked their 10-year manufacturing collaboration on 1 May 2020, the United States had already passed 1.1 million confirmed cases and 65,000 deaths, with cumulative US deaths ultimately exceeding 1.1 million through the end of the public health emergency declaration in May 2023. The pandemic created the largest acute therapeutic and prophylactic unmet need in modern medicine: at deal date there were no approved or authorized vaccines and no proven therapeutics. Operation Warp Speed, announced 15 May 2020, would commit ~$18 billion to accelerate vaccine and therapeutic development at unprecedented speed. mRNA vaccines emerged as the lead candidate platform — Moderna's mRNA-1273 began Phase 1 (NIH NIAID-sponsored) on 16 March 2020, only 63 days after sequence release. The clinical and supply-chain bet was that mRNA, never previously approved for any indication, could leapfrog inactivated, viral-vector and protein-subunit approaches. The manufacturing complexity was substantial: lipid nanoparticle (LNP) encapsulation, cold-chain (-20°C/-70°C) logistics, and capacity for hundreds of millions of doses by Q1 2021 — none of which Moderna alone could deliver from its Norwood, MA pilot plant.

Competitive Landscape

At deal date (1 May 2020), competing COVID-19 vaccine platforms in development included Pfizer-BioNTech's BNT162b2 (mRNA, Phase 1 began 23 April 2020 in Germany; Pfizer's manufacturing partners included its own Andover/Kalamazoo/Puurs sites), AstraZeneca-Oxford's AZD1222 (chimpanzee adenovirus-vectored, partnered manufacturing with Serum Institute of India and Catalent), J&J/Janssen's Ad26.COV2.S (single-dose adenovirus-vectored, Emergent BioSolutions Baltimore manufacturing), Novavax NVX-CoV2373 (recombinant spike protein nanoparticle with Matrix-M adjuvant, Serum Institute manufacturing), Sanofi-GSK's recombinant protein candidate (Sanofi Marcy l'Etoile site), Sinovac CoronaVac and Sinopharm BBIBP-CorV (inactivated whole-virion, China). Contract manufacturing organizations supporting the global vaccine response included Lonza (Moderna), Catalent (Moderna fill-finish, AZ, J&J), Emergent BioSolutions (J&J, AZ — later subject to a 2021 quality crisis at Bayview), Serum Institute of India (AZ, Novavax, Sputnik V), Fujifilm Diosynth, Samsung Biologics, and Recipharm. Lonza's selection by Moderna reflected its global mid-scale biologics capacity, prior mRNA experience, and ability to stand up dedicated US (Portsmouth, NH) and Swiss (Visp) manufacturing kits within the Operation Warp Speed timeline.